BioCardia, Inc. (NASDAQ:BCDA) Short Interest Down 39.6% in January

BioCardia, Inc. (NASDAQ:BCDA) was the recipient of a large drop in short interest during the month of January. As of January 15th, there was short interest totalling 50,400 shares, a drop of 39.6% from the December 31st total of 83,400 shares. Approximately 1.3% of the shares of the company are sold short. Based on an average daily trading volume, of 48,500 shares, the days-to-cover ratio is presently 1.0 days.

Wall Street Analyst Weigh In

Separately, HC Wainwright reiterated a “buy” rating and issued a $25.00 price target on shares of BioCardia in a research report on Wednesday, December 18th.

BioCardia Trading Up 0.4 %

Shares of BCDA opened at $2.28 on Wednesday. BioCardia has a fifty-two week low of $1.63 and a fifty-two week high of $8.85. The firm has a 50-day simple moving average of $2.19 and a 200-day simple moving average of $2.53.

BioCardia Company Profile

BioCardia, Inc, a clinical-stage regenerative medicine company, develops cellular and cell-derived therapeutics for cardiovascular and pulmonary diseases in the United States. Its lead product candidate is CardiAMP, an autologous mononuclear cell therapy system in Phase III clinical trial for the treatment of ischemic heart failure with reduced ejection fraction and refractory angina resulting from chronic myocardial ischemia.